ArticleAmerican journal of industrial medicine2019
Silicosis prevalence and incidence among Medicare beneficiaries.
Article in American journal of industrial medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.BMJ open respiratory research · 2023Pooled it
- Pneumoconiosis incidence and prevalence among US Medicare beneficiaries, 1999-2019.American journal of industrial medicine · 2023Article
- Malignant mesothelioma among US Medicare beneficiaries: incidence, prevalence and therapy, 2016-2019.Occupational and environmental medicine · 2023Article
- Current status, trends, and predictions in the burden of silicosis in 204 countries and territories from 1990 to 2019.Frontiers in public health · 2023Article
- Erasmus Syndrome: A Case Report and Literature Review.The American journal of case reports · 2022Review
- Article
- Current global perspectives on silicosis-Convergence of old and newly emergent hazards.Respirology (Carlton, Vic.) · 2022Review
- RAB20 deficiency promotes the development of silicosisFrontiers in immunology · 2022Article
- Dihydroquercetin Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting Ferroptosis Signaling Pathway.Frontiers in pharmacology · 2022Article
- Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers.Scientific reports · 2021Article
- Transplantation for work-related lung disease in the USA.Occupational and environmental medicine · 2020Article
- Pneumoconiosis ICD-CM Diagnosis Codes on Medicare Claims for Federal Black Lung Program Beneficiaries.Annals of the American Thoracic Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionExisting epidemiologic information on silicosis relies on mortality data.
methodsWe analyzed health insurance claims and enrollment information from 49 923 987 fee-for-service (FFS) Medicare beneficiaries aged ≥65 from 1999 to 2014. Three different definitions were developed to identify silicosis cases and results are presented as ranges of values for the three definitions.
resultsAmong FFS beneficiaries, 10 026-19 696 fit the silicosis case definitions (16-year prevalence: 20.1-39.5 per 100 000) with the highest prevalence among North American Natives (87.2-213.6 per 100 000) and those in New Mexico (83.9-203.4 per 100 000). The annual average prevalence had a significant (P < 0.05) 2-5% annual decline from 2005 to 2014. The average annual number of incident cases had a significant 3-16% annual decline from 2007 to 2014.
conclusionsSilicosis is a prevalent disease among Medicare beneficiaries aged ≥65, with variation across the country. Morbidity data from health insurance claims can provide a more complete picture of silicosis burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.